Schizophrenia is marked by varying levels of positive symptoms (such as hallucinations, delusions, disordered thinking, and agitation), negative symptoms (such as loss of motivation, reduced interest or pleasure in daily activities, flat affect, social withdrawal, difficulty expressing emotions, and reduced speech), and cognitive impairment. Negative symptoms are prominent in about 40% of patients with schizophrenia, while cognitive symptoms are evident in up to 80% of patients. Becoming familiar with the clinical data for novel digital therapeutics, as well as pharmacotherapy under development for cognitive and negative symptoms associated with schizophrenia, will help clinicians prepare for potential approval and early adoption of these novel treatment approaches for those patients who would benefit the most.